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Abstract
Evaluation of pleural fluids for metastatic cells is a key component of diagnostic cytopathology. However, a large
background of smaller leukocytes and/or erythrocytes can make accurate diagnosis difficult and reduce specificity in
identification of mutations of interest for targeted anti-cancer therapies. Here, we describe an automated microfluidic
system (Centrifuge Chip) which employs microscale vortices for the size-based isolation and concentration of cancer cells
and mesothelial cells from a background of blood cells. We are able to process non-diluted pleural fluids at 6 mL/min and
enrich target cells significantly over the background; we achieved improved purity in all patient samples analyzed. The
resulting isolated and viable cells are readily available for immunostaining, cytological analysis, and detection of gene
mutations. To demonstrate the utility towards aiding companion diagnostics, we also show improved detection accuracy of
KRAS gene mutations in lung cancer cells processed using the Centrifuge Chip, leading to an increase in the area under the
curve (AUC) of the receiver operating characteristic from 0.90 to 0.99. The Centrifuge Chip allows for rapid concentration
and processing of large volumes of bodily fluid samples for improved cytological diagnosis and purification of cells of
interest for genetic testing, which will be helpful for enhancing diagnostic accuracy.
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Introduction
The pleural space surrounds the lungs and is lined by the pleural
sac. Under certain conditions, including malignancies, this space
can fill with excess fluid, resulting in a pleural effusion.
Thoracentesis is a procedure to remove this pleural fluid, both
for diagnostic and therapeutic purposes. Over 1.5 million
thoracentesis procedures are conducted annually in the United
States [1]. Many cell types may be present within the pleural
effusion, and identifying and isolating these cells is important to
identify the ongoing disease process. Cytologists analyze pleural
samples to determine the cause (presence or absence of cancer) by
examining stained cell smears on a glass slide. Sample preparation
and analysis requires technician-intensive sample handling involv-
ing multiple centrifugation steps followed by staining and time-
consuming manual microscopic scanning of cytology slides by the
cytopathologist, who must search for key cancer cell morpholog-
ical characteristics, such as high nuclear-to-cytoplasmic ratios,
hypochromatic cytoplasms, and dense, dark nuclei.
Disseminated cancer cells originating from the lung, breast, or
other organs can be identified in malignant pleural effusions.
Traditional cytomorphological analysis of cell smears and blocks
has high specificity, but low sensitivity. The low sensitivity can be
either due to the subjective nature of analysis, loss of tumor cells
during processing, or the fact that there may be few tumor cells
present in a large specimen volume with obscuring blood. In up to
40% of cases, traditional cytological examinations may fail to
identify malignant cells [2]. Therefore, approaches to obtaining
these malignant cells from larger volumes of fluid with high purity
and efficiency could improve cytology-based diagnoses [3].
Additional applications for purified cells from pleural and other
body fluids include the ability to probe cellular properties such as
cell deformability [4,5], evaluation of effusion microenvironments
[6], and identifying cellular metastases [7].
Tumor cells present in effusions may also be the only easily
accessible source of malignant cells following cancer relapse,
particularly in cases where the original mass was removed.
Isolating cancer cells within malignant effusions may therefore be
critical in order to perform molecular analysis or other tests to
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determine the up-to-date mutational status of the cancer that is
crucial for the determination of targeted therapy [8]. Previous
studies have indicated that only a subset of pleural effusions are
suitable for mutational analysis because of the presence of large
quantities of contaminating cells; malignant pleural fluids are
almost always bloody, with large populations of leukocytes and/or
erythrocytes [9]. Specifically, the leukocytes contain wild type
DNA that may interfere with the detection of genetic mutations of
interest [10].
Increasing sample purity enables improved molecular diagnos-
tics to detect the presence of specific genetic mutations which may
be amenable to targeted therapies. This can be achieved by
removing a large population of leukocytes that contain interfering
wild-type DNA. For genetic testing such as quantitative PCR
(qPCR), the presence of a small quantity of mutated genes can be
overshadowed by a large background of wild type nucleic acids.
Using qPCR, the cycle threshold (Ct) gives a relative measurement
of the amount of genetic material of interest that is present; a lower
Ct indicates a greater amount of the gene of interest. Although
qPCR can be exquisitely sensitive for mutation detection given
appropriate selection of amplification primers, there is often some
non-specific amplification from background DNA. The presence
of large quantities of background DNA can thus interfere with
accurate measurement of the Ct due to this non-specific
amplification; this effect may still be notable even after normal-
ization with housekeeping genes.
There are several approaches that are currently utilized to
isolate cells of interest from pleural effusions for molecular analysis.
The gold standard is laser capture microdissection (LCM), a
technique used to isolate pure populations from cytology fluids,
live cell culture, or heterogeneous tissue sections [11,12,13,14,15].
However, this technique requires drying out of cells during
capture, which can lead to cell damage and is not capable of
extracting large quantities of cells for analysis. It is also very time
and labor intensive. Flow cytometry and fluorescence activated cell
sorting (FACS) are also common methods for cell separation and
sorting. While FACS can process samples of up to 30 mL in 1 hr,
the sorted cells may not be suitable for further analysis as a result
of the initial fixing and cell type-specific staining required for the
sorting process. Microfluidic technology is an emerging tool that
may deliver automated, well-controlled platforms to purify target
cells with the highest possible sensitivity and specificity. Several
strategies have been used to isolate and enrich tumor cells in body
fluid [16], such as the use of self-assembled magnetic beads coated
with anti-CD19 antibodies to capture B-cell malignant tumors
[17]. However, current technologies are limited by throughput
and purity, and none have been placed in widespread use in
clinical labs for a variety of reasons. Many devices also focus on
rare cell isolation from blood rather than tumor cell enrichment
from pleural effusions, which have unique fluid properties and
cellular profiles. Ideally, rapid sampling of pleural fluids (often
liters of fluid) requires mL/min processing rates and separation
using a label-free marker such as cell size [18]. Moreover, sample
preparation of pleural effusions should be performed in an
automated, repeatable fashion to enable clinicians and cytopa-
thologists to perform molecular assays on the purified cells with the
highest possible sensitivity and specificity in a short time period
(tens of minutes).
We have previously demonstrated a potentially low cost,
miniaturized microfluidic system that recapitulates the high-
throughput operations of enrichment and concentration of a
standard laboratory centrifuge (the ‘‘Centrifuge Chip’’) [19]. Here,
we use the Centrifuge Chip for the isolation of cancer cells and
mesothelial cells at high purity from pleural effusions as a
preparation step for downstream analysis by traditional cytology
and mutational analysis (Figure 1A). By processing a large
volume of fluid and selectively enriching larger cells over a
background of red and white blood cells we replace the traditional
centrifugation step in the clinical lab while also potentially
enabling more sensitive analysis of purer preparations originating
from large volume samples. Briefly, the approach employs unique
inertial fluid physics to selectively collect larger cells (such as tumor
cells) in laminar fluid microvortices at high rates without clog-
prone filters [19,20] (Figure 1B, Video S1). Smaller leukocytes
and erythrocytes are not stably trapped in vortices and are
significantly reduced in the collected concentrated sample
(Figure 1D). We have also implemented fluid plumbing
automation to process samples and release isolated cells back into
a small volume, under the control of a custom-written software
program (Figure 1C, Figure S1). Each Centrifuge Chip
processes effusions at a flow rate of 6 mL/min and concentrates
larger cells (mesothelial and epithelial). Purified cells are released
and made readily available in a collection vial or micro-titer plate
for cytology and identifying gene mutations.
Materials and Methods
Ethics Statement
The study is exempt from institutional review board approval
because remnants of patient specimens were processed and
analyzed anonymously, with no access to protected health
information, personal identifying information, or sensitive infor-
mation. The study is exempt under 45 CFR 46.101 Category 4,
which includes ‘‘Research involving the collection or study of
existing data, documents, records, pathological specimens, or
diagnostic specimens, if these sources are publicly available or if
the information is recorded by the investigator in such a manner
that subjects cannot be identified, directly or through identifiers
linked to the subjects.’’
(http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.
html#46.101)
Microfluidic Device Fabrication and Setup
Devices were fabricated using standard photolithography and
polydimethylsiloxane replica molding techniques. The devices
were designed in AutoCAD (Autodesk) and printed on a
transparency photomask at 20,000 dots per inch (CAD/Art
Service, Inc.). The mold was photolithographically defined using
this mask in the UCLA Nanoelectronics Research Facility.
Negative photoresist, KMPR 1050 (MicroChem), was spun at
2400 rpm for 30 s on a 10-cm silicon wafer. The wafer was soft-
baked at 100uC for 15 min, exposed under near UV for 30 s, post-
baked at 100uC for 4 min, and developed in SU-8 Developer
(MicroChem). The height of the resulting feature was measured to
be 55 mm using a profilometer (Veeco Metrology). Polydimethyl-
siloxane (PDMS) (Sylgard 184 Dow Corning Corp.) was poured
onto the photoresist master at a 10:1 ratio of base to crosslinker,
degassed in a vacuum chamber, and cured at 65uC overnight. The
devices were then cut from the mold, ports were punched with a
punch kit (Technical Innovations), and the devices were bonded to
glass slides using oxygen plasma for 30 s (Harrick Plasma). After
plasma treatment and placement onto the glass substrate, the
devices were maintained at 65uC in an oven for 15 min to increase
bonding.
Cell Trapping Mechanism
The mechanism of operation is based on size-dependent inertial
lift, which leads to selective entry and stable orbits for larger cells
Microfluidic Purification for Cytodiagnostics
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within vortices created in an expansion reservoir [19,20]. Smaller
cells do not experience sufficient lift force and therefore either do
not enter the vortex, or do not have enough restoring lift force to
remain stable within the vortices in the presence of de-stabilizing
disturbances from other orbiting particles. In our previous work
we identified reservoir geometries and flow conditions to
selectively collect cells and particles above ,15 mm, with capture
efficiencies of ,20% for MCF7 cells spiked in diluted blood [19].
The rectangular reservoirs are 480 mm wide and 720 mm long,
and the straight channels are 40 mm wide. In this work, we made
several device modifications including 1) the integration with a
custom-made pressure system that operates using a simple ‘plug-
and-play’ option in which an operator does not need to be present
at all times, 2) the shortening of the device channel length to
reduce fluidic resistance, and 3) the increase of the number of
parallel channels to 16 with 4 chambers in each channel for a total
of 128 cell trapping reservoirs to process samples at a flow rate of
6 mL/min. At this flow rate one patient sample (,50 ml of
volume) takes ,10 minutes to process. The capture efficiency of
the device was ,47%, which was defined as the number of 20 mm
diameter beads caught and released from the vortices divided by
the total number of beads injected.
Sample Processing using a Computer-Controlled
Pressure System
The device is connected to a custom-made pressure system that
delivers effusion samples or saline wash from pressurized glass
bottles through the Centrifuge Chip (Figure S1). The Labview-
controlled system contains a pair of air regulators, air valves and
liquid valves (SMC Corporation) that brings compressed air into
the bottles and drives fluid through the microchip device. Non-
diluted pleural effusion samples are poured directly into the glass
bottle and introduced through the device at 6 mL/min. Once the
vortex traps are filled with cells, PBS is introduced into the device
to wash out untrapped blood cells in the main flow and the vortex
traps. Cells trapped in the fluid vortex are released by reducing the
input air pressure and subsequently lowering the flow rate and
dissipating the vortex. We implement a ‘trap-and-release’ program
that can continuously introduce sample through the Centrifuge
Chip, wash, and release the captured cells in a small 250 mL
volume into a microtiter plate or collection vial. A video of sample
processing was recorded using Phantom Camera Control and
Software (Vision Research Inc.) with a high-speed camera
(Phantom v7.3).
Sample Collection and Preparation
Remnants of 115 pleural effusion samples obtained from
Ronald Reagan UCLA Medical Center, Santa Monica UCLA
Medical Center, and Northridge Hospital Medical Center were
used in our study. From all specimens, up to 50 mL of sample
were processed with the Centrifuge Chip. Effusions were passed
through a 40 mm cell strainer before introducing through the
Centrifuge Chip system. Half of the processed samples were
returned to the cytology laboratory to create cell smears. This was
performed in parallel with cell smears produced with traditional
cytological methods on original, unprocessed samples. The other
half of processed samples were fluorescently labeled to quantify
sample purity (Figure S2). A fraction of samples were profiled for
cell size distributions before and after processing.
Cell Smear Preparation and Imaging
Smears were prepared according to normal methods to prepare
samples for clinical evaluation. Briefly, samples were aliquoted into
50 mL conical tubes and centrifuged down with a standard
benchtop centrifuge. After centrifugation, the supernatant is
aspirated and the cells are resuspended in a buffer solution and
placed with a glass slide into a cytocentrifuge (Thermo Scientific)
to create a cell smear. The cell slides are air dried or fixed and
stained with Papanicolou (Pap) or May-Grunwald-Giemsa (MGG)
stains.
Figure 1. Principles of the Centrifuge Chip. (A) A photograph of the Centrifuge Chip device. Only a single inlet and outlet is required. (B) A
schematic of the massively parallel microfluidic device that selectively traps large cells in individual microscale vortices. (C) A photograph of the
device connected to an automated fluidic instrument to deliver patient pleural samples and saline wash through the Centrifuge Chip into the waste
bottle or collection plate. Trapped epithelial and mesothelial cells are made readily available i) into a collection tube for further cytology slide
comparisons with the original and/or ii) into a well-plate for immunolabeling, imaging and analysis. (D) High-speed microscopic image showing
trapping of larger single and clumped cells while smaller red and white blood cells pass through.
doi:10.1371/journal.pone.0078194.g001
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Fluorescent Staining for Purity Measurements
For each specimen, 300 mL of the original effusion was
transferred into one well of a 96-well microtiter plate. To compare
the processed sample versus the original sample, up to 10 mL
effusion volume was processed with the Centrifuge Chip and
isolated cells were released in a volume of ,250 microliters in the
microtiter plate. To determine the composition of the cell
population, leukocyte, epithelial and nuclear stains were used.
After centrifuging the cells to the bottom of the well with a plate
centrifuge (Beckman Coulter), the supernatant was aspirated. Cells
were treated with 4% v/v formaldehyde for 15 min, permeabi-
lized with 0.4% v/v Triton X-100 (Sigma-Aldrich) for 7 min, and
incubated with cytokeratin (CK)-PE (epithelial and mesothelial
cells), CD45-FITC (white blood cells), and DAPI (nucleus)
(Invitrogen) in 2% w/v BSA. Between each step, cells were
sedimented with the centrifuge and washed with PBS. After
staining, the cells were imaged using a CCD camera (Photometrics
CoolSNAP HQ2) mounted on a Nikon Eclipse Ti microscope.
The whole well was automatically imaged in a few minutes (100X)
using an ASI motorized stage operated with Nikon NIS-Elements
AR 3.2 software. Captured images were automatically obtained
for four configurations: brightfield, FITC, TRITC and DAPI filter
sets. Collected images were automatically stitched together using
the NIS-Elements Software. Images were analyzed by enumerat-
ing the number of CK+ and CD45+ cells present in each well.
Purity is defined as the number of CK+ cells divided by the total
number of nucleated cells. CK+ cells include carcinoma cells and
mesothelial cells. We did not attempt to separate tumor cells from
mesothelial cells as these cells share a similar size, but these
separations can be carried out using IHC markers such as
Calretinin [21], if necessary, to further enrich a specimen.
Quantification of Cell Size
Dilute volumes of unprocessed and processed pleural samples
were lysed with red blood cell lysis buffer (Roche) and incubated
with Calcein AM (Invitrogen) for 15 minutes. Cells were imaged
using a Nikon Eclipse Ti fluorescent microscope, and cell sizes
were automatically measured using Nikon NIS-Elements AR 3.2
software.
Detection of KRAS Gene Mutations in Spiked Pleural
Effusion Samples
We evaluated the performance of the Centrifuge Chip to
improve the accuracy of mutational analysis by extracting
molecular information from spiked pleural effusions before and
after enrichment to determine the potential improvement to
qPCR measurement provided by high purity capture. Initial cell
concentration was quantified from a small pleural sample aliquot
using a hemacytometer after performing a red blood cell lysis step.
A549 lung cancer cells (ATCC) were spiked at 0.1% purity in
50 mL of pleural effusions diagnosed as negative for malignancy.
Spiked samples were evaluated for a known activating mutation
in KRAS found in A549 cells, which can provide resistance to
targeted therapies [11]. Specifically, we looked at the 34 G.A
substitution in KRAS (KRAS*) as identified by the Sanger Cosmic
database [22]. We utilized quantitative RT-PCR to identify
mutant KRAS in the A549 cells versus wild type (in HeLa and
other cells) using a modification of the system described by Morlan
et al. (2009) [23]. We used a primer complementary to the mutant
and a blocking primer with a nonhydrolyzable phosphate group
complementary to the wild type sequence which was present at
four times the concentration. The rationale for this strategy was
that the non-hydrolyzable primer would block non-specific
amplification from the wild type sequence while still allowing
amplification from the mutant of interest. GAPDH mRNA was
also amplified as an indicator for the relative number of cells in a
given sample and used to normalize each measurement to
determine the DCt value.
Briefly, reverse transcription was performed using a SuperScript
III RT kit (Invitrogen) according to the manufacturer’s instruc-
tions to create cDNA libraries. TaqMan PCR was performed
using 2 uL of the RT product in a 20 uL total volume with 16
TaqMan Universal PCR Master Mix (no UNG) (Roche) with the
primers at 900 nM, TaqMan probe at 200 nM, and blocker at
3600 nM. Stock TaqMan probes for GAPDH and KRAS were
obtained from Applied Biosystems and used without modification.
The thermocycling conditions were as follows: 10 minutes at 95uC,
40 cycles of 20 seconds at 95uC and 1 minute at 60uC.
Results and Discussion
Measurement of Cell Size Distributions in Pleural
Effusions
Our system operates by selectively isolating cells above a
particular size threshold [19,20]. Therefore, we first measured
detailed information on the number and diameter of cells present
in 25 pleural fluid samples (Figure 2). Possible cytological
diagnoses for pleural effusions included: positive for malignancy,
suspicious or equivocal (atypical) for malignancy, and negative for
malignancy (Table 1). Patient samples diagnosed as negative for
malignancy were often concurrently diagnosed with acute
inflammation, chronic inflammation, or lymphocytosis. Cytolog-
ically, samples with acute inflammation were associated with an
increased neutrophil population; those with chronic inflammation
were associated with a larger fraction of lymphocytes and
histiocytes, while those with lymphocytosis were associated with
increased lymphocytes. In cases positive for malignancy, the tissue
of origin was often known from patient history.
We observed a population of cells greater than 15 mm in
malignant samples (Figure 2A), consistent with the observation
that malignant and mesothelial cells are usually larger compared
to other cells present within these fluids [24]. Cases of
inflammation had a large population of 10–15 mm cells, poten-
tially representing the characteristic population of large activated
immune cells. Of the samples diagnosed as Positive for Malig-
nancy, on average 36.57% of nucleated cells were larger than
15 mm. A lower percentage of larger cells was present in samples
diagnosed as Negative and Negative with Inflammation (32.47%
and 26.92% of nucleated cells larger than 15 mm, respectively).
Cases with inflammation are known to have a larger number of
white blood cells as a fraction of the population, thus leading to a
lower relative percentage of larger cells than negative samples
alone. Note that these relatively large percentages of larger cells in
non-malignant samples are likely the result of the presence of
mesothelial cells and large activated leukocytes. Still, malignant
samples contain the largest fraction of large cells such that cell size
is a potential biomarker for harvesting malignant cells from pleural
fluid samples. The Centrifuge Chip enriches for the cell
populations greater than 15 mm (Figure 2B).
The Centrifuge Chip Increases Purity of Clinical Samples
Qualitatively, the Centrifuge Chip delivered a higher purity
sample compared to unprocessed or centrifuged specimens
(Figure 3A–C). The device increased purity in all 66 cases
examined (100%) (Figure 3D, Table S1). Paired t-tests between
unprocessed and processed samples demonstrated a significant
increase in purity, with p values less than 0.05 for all diagnoses.
Microfluidic Purification for Cytodiagnostics
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In agreement with our cell size measurements, we observed
many cells captured for malignancy-positive cases and fewer for
malignancy-negative cases with lymphocytosis, reactive changes,
or acute inflammation. Additionally, the purity increased from
unprocessed to Centrifuge Chip processed specimens (Table 2).
Purity fold is defined as the purity of a chip-concentrated sample
over the initial unprocessed sample. Greater than 65-fold increase
was observed for samples diagnosed as positive for malignancy.
Interestingly, samples with chronic inflammation had a 132-fold
increase as a result of the larger leukocyte populations in the initial
samples with ,1% purity. Higher purities can be achieved by
increasing the critical size cutoff of the Centrifuge Chip to further
reduce leukocyte capture, although at the cost of potentially not
trapping smaller malignant cells of interest.
Reduced Nonspecific Background from Cytology Slides
and Reduced Sample Area
We addressed issues of reducing background cell populations
and limiting the area of microscopic evaluation by using the
Centrifuge Chip to create concentrated and low background cell
smears. In all samples, malignant and mesothelial cells are found
amongst a cellular background of red and white blood cells in
standard cytology slides while there are few background cells
observed in the Centrifuge Chip-prepared sample slides
(Figure 4A–F). As expected from our cell measurements above,
we concentrated mesothelial and malignant cells in samples
diagnosed as positive for malignancy (Figure 4A–C). Malignant
cells are characterized by large nuclei and high nuclear-
cytoplasmic ratio. Malignant cells are often seen as cell aggregates
or clumps in effusions [1] and these cell populations were also
collected with the Centrifuge Chip. The Centrifuge Chip may aid
pathologists in rapid visualization of rarer malignant cells which
may improve diagnostic sensitivity especially by enabling process-
ing of larger volumes of fluid into a minimal final concentrated
sample volume.
Effect of Purity on KRAS Gene Mutation Detection
Non-specific amplification from background cells can reduce
confidence when measuring the presence of mutations. Pure
populations of 105 A549 cells which contain the KRAS* mutation
and HeLa cells which have wild type KRAS were measured to
have threshold cycles (Ct) of 24.10 and 32.53 respectively (the
latter value indicating nonspecific amplification for wild type
KRAS from HeLa cells). In mixed samples of A549 and HeLa we
found that the presence of the specific KRAS mutation could be
distinguished from background at as low as 0.1% purity of A549
cells, with as few as 10 A549 cells present (Figure S3). Note that the
Figure 2. Distribution of Cell Size in Pleural Fluids and Enrichment with the Centrifuge Chip. (A) Normalized frequency distributions of
nucleated cells in relation to cell diameter are plotted for pleural effusions analyzed within 24 hours of collection and diagnosed as negative (blue,
solid), inflammation (chronic and acute, green, dashed), or malignant (red, dotted). Relative to negative pleural effusions, malignant samples contain
a larger population fraction of cells greater than 15 mm, and cases of inflammation contain a larger population of cells between 10–15 mm. N= 13, 9,
and 10 for negative, inflammation, and malignant cases. (B) The frequency distributions of the same samples after processing through the Centrifuge
Chip were subtracted by the distributions before processing to observe enrichment. The device enriches for cell populations greater than 15 mm and
depletes smaller cells.
doi:10.1371/journal.pone.0078194.g002
Table 1. Summary of 115 Pleural Samples Analyzed in the
Study.
Cytodiagnosis Classification
Total
Cases
Positive 25
Lung 10
Breast 6
Ovarian 3
Gastric 2
Pancreatic 2
Esophageal 1
Mesothelioma 1
Suspicious 13
Negative 77
Chronic Inflammation 25
Lymphocytosis 15
Reactive Changes 10
Acute Inflammation 9
TOTAL 115
25/115 (21.7%) of samples were diagnosed positive for malignancy, 13/115
(11.3%) were diagnosed suspicious for malignancy, and 77/115 (67.0%) were
diagnosed negative for malignancy.
doi:10.1371/journal.pone.0078194.t001
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same Ct values can be observed from low numbers of A549 cells
with specific amplification occurring, or large numbers of HeLa
cells with non-specific amplification (see 10,000 HeLa cells vs. 10
A549 cells, Figure S3A). Therefore, we normalized the data to
account for cell number by subtracting GAPDH Ct from KRAS
Ct values, yielding a KRAS* DCt. As expected, increased purity
samples yielded improved results, characterized by a lower DCt
(Figure S3B).
The Centrifuge Chip also improved the sensitivity and
specificity in detecting A549 cells spiked into negative clinical
effusion samples at 0.1% purity (Figure 5). Unspiked negative
samples (including acute and chronic inflammation samples)
averaged a KRAS* DCt of 15.761.76 (N = 7), and spiked samples
at 0.1% purity averaged 12.861.39. Once processed with the
Centrifuge Chip, the KRAS* DCt decreased and became further
differentiated from the negative samples in all cases (Figure 5A)
with an average of 9.661.19 DCt. Average GAPDH Ct values
were 17.6362.10, 17.8062.05, and 23.7562.03 for negative
samples, unprocessed spiked samples, and processed spiked
samples, respectively. A paired, t-test between non-spiked and
spiked samples demonstrated improved statistical significance in
the difference in the average KRAS* DCt after spiked samples
were processed with the Centrifuge Chip (p = 0.0027 before and
p = 1.44e26 after processing). Moreover, using a Gaussian
distribution fit to DCt values for each group of samples, receiver
operating characteristic curves (Figure 5B) demonstrated im-
proved area under curve (AUC) values from 0.905 (unprocessed
spiked samples) to 0.998 (processed spiked samples). The upper
Figure 3. Paired Samples Following Centrifuge Chip Processing Show Purity Increases. (A–C) Qualitative comparison of unprocessed
sample, centrifuged sample, and sample processed with the Centrifuge Chip. Immunofluorescent images of Cytokeratin (CK, red – epithelial cells),
CD45 (green – leukocytes), and DAPI (blue – nucleus). Insets show well-plate color: yellow (fresh specimen), red (indicating bloody) and colorless
(after processing with device). Arrows indicate CK+/DAPI+ epithelial cells. (D) Purity increases upon processing with the Centrifuge Chip. Purity is
defined as the presence of CK+/DAPI+ (epithelial and mesothelial cells) over the total number of cells. All samples (N = 66) were seen to increase in
purity after processing with the Centrifuge Chip. Red and blue bars represent the average purity.
doi:10.1371/journal.pone.0078194.g003
Table 2. Purity Increases Following Processing with the
Centrifuge Chip.
Cytodiagnosis Purity fold increase
Positive 65.38
Suspicious 34.05
Negative 20.46
Lymphocytosis 20.66
Acute Inflammation 27.93
Chronic Inflammation 132.03
Reactive Changes 10.39
Purity fold is defined as the ratio of purities between a specimen processed
with the Centrifuge Chip and the unprocessed specimen.
doi:10.1371/journal.pone.0078194.t002
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cutoff threshold for a positive KRAS* DCt diagnosis was
determined by maximizing both sensitivity and specificity, and it
was found to be 14.1 for unprocessed and 12.2 for processed
samples. By increasing sample purity with the device, we are able
to improve KRAS mutation detection and diagnostic confidence.
For a highly specific assay like PCR, our simple concentration
approach has the potential to improve diagnostic accuracy for
mutational detection when the original mutation is known (e.g., in
a sequenced tumor). We expect our technique will be particularly
useful in less specific assays, such as gene sequencing, if a
particular gene mutation is suspected but the source unknown. As
next generation sequencing technologies improve, it may even be
possible to do whole transcriptome sequencing, and achieving high
purity using an approach such as this would be essential to detect
mutations of interest while suppressing non-specific wild-type
reads.
Conclusions
We have developed the Centrifuge Chip, a microfluidic device
which can rapidly isolate larger, potentially malignant cells from
pleural effusions in a label-free manner with high purity, using size
as a biomarker. This chip has several advantages over currently
available techniques including speed, robust operation, and ability
Figure 4. Reduced Background Cytology Slides When Prepared Using the Centrifuge Chip. Unprocessed patient samples are prepared
with traditional cytological techniques using Papanicolaou (Pap) and May-Grunwald–Giemsa (MGG) stains. Cells collected from samples processed
with Centrifuge Chip were also made into cytology slides. In all samples, malignant and mesothelial cells are found amongst a cellular background of
immune cells in standard slides while little background is observed in the Centrifuge Chip slide. In samples diagnosed as ‘positive for malignancy’,
single and clumped malignant cells (red arrows) are retrieved following the Centrifuge Chip. In patients diagnosed as ‘negative for malignancy’,
mesothelial cells (green arrows) were found amongst a background of blood cells in standard slides, compared to no blood cell background upon
Centrifuge Chip Processing. Samples diagnosed as atypical contained cells which resembled either malignant or mesothelial cells (blue arrows).
Images obtained at 2006magnification.
doi:10.1371/journal.pone.0078194.g004
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to process large volumes of sample and concentrate cells into a
small end volume. We were able to prepare effusion specimens in
ten minutes, an order of magnitude faster than other similar
techniques, with increased purity. We also demonstrated that
processing by the chip provides improved accuracy detection of
mutations with qPCR. This system allows for rapid purification
and isolation of cells of interest and has the potential to enable
cytopathologists, clinicians, and researchers access to purified cells
for preparing cytology slides, detecting specific gene mutations for
targeted drug therapies, culturing cells for further analysis, or even
isolating of single cells for next generation sequencing analysis at
lower cost than currently available techniques. Improved muta-
tional detection at lower cost from readily available body fluids
provides a compelling route towards making targeted anti-cancer
therapies a broad clinical reality.
Supporting Information
Figure S1 Centrifuge Chip System Schematic and
Operations. Sample processing is controlled using an automated
pressure system comprised of an air tank, pressure regulators, air
and liquid valves, and a computer with a LabVIEW (National
Instruments) user interface. A liquid valve upstream from the
device switches between the saline wash and pleural sample
bottles, and the downstream valve directs fluid between the waste
and collection containers. The procedure involves three key steps,
including: i.) processing the fluid sample to capture potential
cancer cells, ii) washing the device reservoirs to remove smaller
leukocytes and RBCs while maintaining the same flow rate and
active microvortices to keep larger cells trapped, and iii) lowering
the flow rate to release the captured cells from the vortices and into
a 96-well plate.
(TIF)
Figure S2 Sample Processing Flow with the Centrifuge
Chip. 50 mL of pleural effusion sample were processed using
traditional cytological methods and the Centrifuge Chip. A
portion of cells harvested from the Centrifuge Chip was returned
to the cytopathology laboratory to create cell smears; the other
portion of processed sample was immunolabeled for purity
analysis.
(TIF)
Figure S3 Effect of cell number and purity on PCR. (A)
Quantitative RT-PCR was performed on cell lines with varying
cell number. Ct values for KRAS* (solid line) and GAPDH (dotted
line) decreased with increasing cell number. KRAS* Ct for
samples with 1,000 HeLa cells or fewer was not detected. (B)
KRAS* DCt decreases with increasing purity of A549 cells spiked
in a larger population of HeLa cells.
(TIF)
Video S1 Microfluidic processing of a pleural effusion.
A real-time video is shown for Centrifuge Chip processing of a
bloody patient pleural effusion specimen. The microfluidic chip is
first primed with an isotonic solution, and the automated pressure
setup and computerized system controls i) patient sample infusion,
ii) solution exchange, and iii) cell release. When the sample is
initially infused, the flow rate increases until vortices develop,
which is apparent when cells begin to occupy two lateral vortices
beside the central flow stream. Next, an upstream valve switches
the injection fluid from the specimen bottle to the isotonic wash
bottle. During the solution exchange, the remaining small blood
cells are observed to wash away, leaving only the stably trapped
large cells. Finally, cells are collected off-chip by lowering the wash
flow rate to dissipate the vortices and release the cells. The process
is repeated as necessary to collect more cells or to process the
entire patient sample. Sample infusion time is adjusted for each
specimen so that microvortices do not become over-saturated with
cells prior to release; infusion times used in this study ranged from
10 seconds to 3 minutes, depending on the sample cellularity.
(WMV)
Table S1 Complete Summary of 115 Patient Pleural
Fluids Used in the Study. Pos = positive for malignancy,
Sus = suspicious for malignancy, N = negative for malignancy,
R = reactive changes, L = lymphocytosis, CI = chronic inflam-
mation, and AI = acute inflammation. Purity is defined as the
number of CK+/DAPI+ cells over the total number of cells.
(DOC)
Figure 5. Enhanced RT-PCR Detection Confidence Using the Centrifuge Chip. (A) RT-PCR was performed on non-spiked, unprocessed
spiked samples (0.1% purity), and processed spiked samples. KRAS* DCt decreased in all cases (n = 7), demonstrating an improved signal for the KRAS
mutation. Compared to non-spiked samples, processed spiked samples exhibit a clearer KRAS* DCt which is more distinct than for unprocessed
spiked samples. The dotted black line shows a 12.2 Ct cut-off threshold for the KRAS mutation. (B) Receiver operating characteristic curves are plotted
based on a Gaussian distribution of samples shown in part A. Processed samples show higher area under curve (AUC) values at 0.998 (blue, solid),
compared with 0.905 (red, dashed) for unprocessed samples.
doi:10.1371/journal.pone.0078194.g005
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